Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations

Journal of Neurology

Volumn 255, Issue 10, 2008, Pages 1449-1463

  Wiendl, H ^a,b   Toyka, K V ^a,b   Rieckmann, P ^a,b   Gold, R ^a,b   Hartung, H P ^a,b   Hohlfeld, R ^a,b   Baumhackl, U ^b   Berger, T ^b   Deisenhammer, F ^b   Fazekas, F ^b   Freimuller M ^b   Kollegger, H ^b   Kristoferitsch, W ^b   Lassmann, H ^b   Markut, H ^b   Strasser Fuchs, S ^b   Vass, K ^b   Sindic, C ^b   D'hooghe, M B ^b   Podobnik, S ^b   Havrdova, E ^b   Elovaara, I ^b   Clanet, M ^b   Confavreux, C ^b   Edan, G ^b   Lubetzki, C ^b   Altenkirch, H ^b   Bamborschke, S ^b   Baum, K ^b   Bayas, A ^b   Benecke, R ^b   Bruck W ^b   Buttmann, M ^b   Chan, A ^b   Daumer, M ^b   Dommasch, D ^b   Elias, W G ^b   Fasshauer, E ^b   Flachenecker, P ^b   Haas, J ^b   Haferkamp, G ^b   Haller, P ^b   Heesen, C ^b   Heibel, M ^b   Heidenreich, F ^b   Hemmer, B ^b   Henze, T ^b   Janzen, R W C ^b   Japp, G ^b   Jung, S ^b   Jugelt E ^b   Kallmann, B ^b   Kieseier, B C ^b   Kleinschnitz, C ^b   Kohler J ^b   Kohler W ^b   Kolmel W ^b   Konig N ^b   Lehrieder, G ^b   Leussink, V ^b   Lowitzsch, K ^b   Maurer M ^b   Manegold, U ^b   Melms, A ^b   Mertin, J ^b   Meuth, S G ^b   Neuhaus, O ^b   Oschmann, P ^b   Petereit, H F ^b   Pette, M ^b   Pohlau D ^b   Pohl, D ^b   Ruprecht, K ^b   Sailer, M ^b   Schipper, H ^b   Schmidt, S ^b   Schock, G ^b   Schulz, M ^b   Schwarz, S ^b   Schwendemann, G ^b   Seidel, D ^b   Sommer, N ^b   Stangel, M ^b   Stark, E ^b   Steinbrecher, A ^b   Stoll, G ^b   Tumani, H ^b   Voltz, R ^b   Weber, F ^b   Weilbach, F ^b   Wietholter H ^b   Wildemann, B ^b   Zettl, U K ^b   Ziemssen, T ^b   Zipp, F ^b   Zschenderlein, R ^b   Orologas, A ^b   Guseo, A ^b   Bergmann, S ^b   Pugliatti, M ^b   Myhr, K M ^b   Izquierdo, G ^b   Bassetti, C ^b   Beer, K ^b   Beer, S ^b   Buettner, U ^b   Chofflon, M ^b   Gass, A ^b   Goebels, N ^b   Gotschi Fuchs M ^b   Kappos, L ^b   Kesselring, J ^b   Ludin, H P ^b   Mattle, H ^b   Schluep, M ^b   Vaney, C ^b   Bates, D ^b   more..

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NONE

Author keywords

Glatirameracetate; Immunotherapy; Interferon ; Monoclonal antibodies; Multiple sclerosis; Randomized trials; Treatment escalation

Indexed keywords

ALEMTUZUMAB; ATORVASTATIN; AZATHIOPRINE; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; GLUCOCORTICOID; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; LAQUINIMOD; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT BETA INTERFERON; RITUXIMAB; SIMVASTATIN; TERIFLUNOMIDE; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANTIBODY TITER; AUTOIMMUNE THYROIDITIS; CARDIOMYOPATHY; CLINICAL TRIAL; COMPARATIVE STUDY; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEUKEMIA; LONG TERM CARE; LOW BIRTH WEIGHT; MONOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; AZATHIOPRINE; EUROPE; HEALTH PLANNING GUIDELINES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MITOXANTRONE; MULTIPLE SCLEROSIS; PEPTIDES; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIETIES;

EID: 56349150992     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0061-1     Document Type: Review

References (125)

1. MSTCG, et al. (2004) Escalating immunotherapy of multiple sclerosis - New aspects and practical application. J Neurol 251:1329-1339
2. MSTCG, et al. (2006) Symptomatic Treatment of Multiple Sclerosis. Eur Neurol 56:78-105
3. Goodin 2002 Neurology 58 169
4. McDonald 2001 Ann Neurol 50 121
5. Dalton 2002 Ann Neurol 52 47
6. Tintore 2003 Neurology 60 27
7. Polman 2005 Mult Scler 11 5
8. Polman 2005 Ann Neurol 58 840
9. Wiendl 2006 Nervenarzt 77 1237
10. Berger 2003 N Engl J Med 349 139
11. Gaertner 2004 Neurology 63 2381
12. Lampasona 2004 Neurology 62 2092
13. Rauer 2006 J Neurol Neurosurg Psychiatry 77 739
14. Kuhle 2007 N Engl J Med 356 371
15. Lim 2005 Mult Scler 11 492
16. Lennon 2004 Lancet 364 2106
17. Nakashima 2006 J Neurol Neurosurg Psychiatry 77 1073
18. Paul 2007 PLoS Med 4 e133
19. Matsuoka 2007 Brain 130 1206
20. Lucchinetti 2002 Brain 125 1450
21. Fuhr 2001 Brain 124 2162
22. Kallmann 2006 Mult Scler 12 58
23. Kappos 2006 Neurology 67 1242
24. Anonymus (2006) Europäische Kommission genehmigt Aktualisierung der therapeutischen Indication für Rebif® www.serono.com/content/media/ downloads/2006/20060710_de.pdf
25. Kappos 2007 Lancet 370 389
26. Rio 2005 J Neurol 252 795
27. Kinkel 2006 Neurology 66 678
28. Pohl 2005 Neurology 64 888
29. Ghezzi 2005 Mult Scler 11 420
30. Tenembaum 2006 Neurology 67 511
31. Banwell 2006 Neurology 66 472
32. Sandberg-Wollheim 2005 Neurology 65 802
33. Boskovic 2005 Neurology 65 807
34. Clanet 2002 Neurology 59 1507
35. Clanet 2004 Mult Scler 10 139
36. Freedman 2005 Mult Scler 11 41
37. Vartanian 2003 Clin Ther 25 105
38. Panitch 2002 Neurology 59 1496
39. Panitch 2005 J Neurol Sci 239 67
40. Schwid 2005 Arch Neurol 62 785
41. Durelli 2002 Lancet 359 1453
42. Koch-Henriksen 2006 Neurology 66 1056
43. Bertolotto 2004 Curr Opin Neurol 17 241
44. Sorensen 2005 Neurology 65 33
45. Sorensen 2003 Lancet 362 1184
46. Sorensen 2005 Eur J Neurol 12 817
47. Polman 2003 Neurology 60 37
48. Francis 2005 Neurology 65 48
49. Kappos 2005 Neurology 65 40
50. Koch 2007 Neurology 68 1163
51. Hemmer 2005 Lancet Neurol 4 403
52. Khan 2001 Mult Scler 7 349
53. Haas 2005 Eur J Neurol 12 425
54. Vallittu 2005 Acta Neurol Scand 112 234
55. Flechter 2002 J Neurol Sci 197 51
56. Cohen 2007 Neurology 68 939
57. Ramtahal 2006 J Neurol 253 1160
58. Ziemssen 2004 Adv Exp Med Biol 541 111
59. Aharoni 2005 Proc Natl Acad Sci USA 102 19045
60. Khan 2005 Mult Scler 11 646
61. Wolinsky 2007 Ann Neurol 61 14
62. Filippi 2006 Lancet Neurol 5 213
63. Simmons 2005 Curr Opin Pharmacol 5 398
64. Ropper 2006 N Engl J Med 354 965
65. Yednock 1992 Nature 356 63
66. Theien 2001 J Clin Invest 107 995
67. Miller 2003 N Engl J Med 348 15
68. Rudick 2006 N Engl J Med 354 911
69. Polman 2006 N Engl J Med 354 899
70. Ransohoff 2005 Nat Neurosci 8 1275
71. Yousry 2006 N Engl J Med 354 924
72. Khalili 2006 Mult Scler 12 133
73. Mullen 2008 N Engl J Med 358 647
74. BI GmbH BI (2008) http://www.biogenidec.com/site/products-on-the-market. html
75. European Medicines Agency (EMEA) (2008) EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/humandocs/Humans/EPAR/tysabri/ tysabri.htm
76. Ghalie 2002 Neurology 59 909
77. Ghalie 2002 Mult Scler 8 441
78. Cocco 2007 Mult Scler 13 975
79. Scott 2004 CNS Drugs 18 379
80. Kappos 2007 Lancet Neurol 6 431
81. Gold 2007 J Neuroimmunol 187 156
82. O'Connor 2004 Neurology 62 2038
83. O'Connor 2006 Neurology 66 894
84. Kappos 2006 N Engl J Med 355 1124
85. Sipe 2005 Expert Rev Neurother 5 721
86. Rose 2007 Neurology 69 785
87. Bielekova 2004 Proc Nat Acad Sci USA 101 8705
88. Rose 2004 Ann Neurol 56 864
89. Hauser 2008 N Engl J Med 358 676
90. Bar-Or 2008 Ann Neurol 63 395
91. Coles 2006 J Neurol 253 98
92. Coles 2007 Neurology 68 A100
93. Hirst 2008 J Neurol 255 231
94. Markovic-Plese 2003 Neurology 60 1849
95. Pulicken 2005 Mult Scler 11 169
96. Calabresi 2002 Neurology 58 314
97. Jeffery 2004 Neurology 63 S41
98. Smith 2005 Mult Scler 11 573
99. Jeffery 2005 Mult Scler 11 296
100. Perini 2006 J Neurol 253 1034
101. Sorensen 2003 Neurol Sci 24 S227
102. Achiron 2004 Arch Neurol 61 1515
103. Hommes 2004 Lancet 364 1149
104. Sorensen 2004 Neurology 63 2028
105. Stangel 2005 Int MS J 12 5
106. Haas 2007 Mult Scler 13 900
107. Achiron 2004 J Neurol 251 1133
108. Haas 2000 Mult Scler 6 S18
109. Hartung 2002 The Lancet 360 2018
110. Krapf 2005 Neurology 65 690
111. Avasarala 2003 Mult Scler 9 59
112. Paul 2007 J Neurol Neurosurg Psychiatry 78 198
113. Edan 1997 J Neurol Neurosurg Psychiatry 62 112
114. Le Page 2008 J Neurol Neurosurg Psychiatry 79 52
115. Confavreux 1996 Neurology 46 1607
116. Massacesi 2005 Arch Neurol 62 1843
117. Vermersch 2005 Lupus 14 S42
118. Frohman 2004 Clin Neuropharmacol 27 80
119. Rowin 2006 Neurology 66 1245
120. Vollmer 2004 Lancet 363 1607
121. Ruprecht 2004 Neurology 63 1081
122. Lehmann 2006 Arch Neurol 63 930
123. Comi 2006 Clin Neurol Neurosurg 108 339
124. Tomassini 2006 J Neurol 253 287
125. Filippi 2006 Eur J Neurol 13 313